<DOC>
	<DOC>NCT02193490</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.</brief_summary>
	<brief_title>DNase Treatment for Dry Eyes</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Aged 18 years or older. Capable of giving informed consent and does provide informed consent. Documented Dry Eye Disease for at least 6 months. Schirmer I &lt;10 Corneal/ conjunctival (Rose Bengal) staining ≥1 Ocular symptoms must be considered as annoying or activity limiting (OSDI ≥13; mild). Women must be postmenopausal ≥ 1 year, or surgically sterilized. If not, a negative urine pregnancy test is required within 14 days of receiving her first dose of test medication (placebo/ study drug) along with definite evidence of contraceptive use during the duration of the study. Allergic to Deoxyribonuclease eye drops or any similar products, or excipients of Deoxyribonuclease eye drops 0.1%. Receiving or have received within 30 days any experimental systemic medication. Active ocular infection or ocular allergies. Any history of eyelid surgery or ocular surgery within the past 3 months. Corneal epithelial defect larger than 1 mm2 in either eye. The use of topical cyclosporine or corticosteroids within 2 weeks of enrollment Have active drug/alcohol dependence or abuse history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DNase, Pulmozyme, dry eye disease, treatment</keyword>
</DOC>